# Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer

> **NCT06542549** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Anhui Provincial Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Advanced Ovarian Cancer
- AK104(PD-1/CTLA-4 Bispecial Antibody)
- Chemotherapy
- Efficacy
- Safety

## Interventions

- **DRUG:** AK104

## Key facts

- **NCT ID:** NCT06542549
- **Lead sponsor:** Anhui Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2027-10-31
- **Final completion:** 2030-10-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06542549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06542549, "Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06542549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*